$ACLS

Axcelis Technologies (ACLS) reported $839M revenue in 2025, with $570M in cash and minimal debt. It announced a $35M investment in a new ion implantation factory in Korea, expected to start production in late 2028. Q2 2026 revenue rose, but EPS fell to $0.75 from $0.98, with gross margin slipping to 42.4%. The company expects revenue growth in 2026-2027, guided at $230M for Q3. Hedge funds increased holdings, while short interest remains at 6.70%.

Axcelis Technologies (ACLS) shares fell despite announcing a $35M investment in a new South Korea plant to boost ion implantation capacity. Investors are concerned about higher spending and execution risks. The company's strong balance sheet may support long-term growth, but profitability has declined, making it more vulnerable to semiconductor cycle fluctuations.

Axcelis Technologies (ACLS) EVP Christopher Tatnall had 136 shares withheld to pay taxes on RSU vesting, valued at $105.04 per share. He retains 27,491 shares, including 20,590 unvested shares subject to forfeiture. The RSUs were granted in 2023 under the 2012 Equity Incentive Plan.

Axcelis Technologies (ACLS) shares fell 22.4% over the past month despite Q2 revenue growth of 10.6% and improved bookings. Margins declined, and backlog remains weak. Management expects mid-single-digit revenue growth in 2026. Memory and power demand show recovery potential, but customer concentration and China exposure add volatility.

Axcelis Technologies (ACLS) plans to invest $35M in a new facility in South Korea to expand manufacturing. The move aims to improve customer responsiveness and add capacity near Asian chipmakers. South Korea contributed 26% of Q2 revenues. ACLS reported Q2 bookings up 36.1% YoY, but backlog and margins declined. The company has $577M in liquidity to support investments.

Axcelis Technologies (ACLS) expects mid-single-digit revenue growth in 2026 and 2027, with 2027 estimates at $981M and EPS of $5.29. Aftermarket revenue grew 35% YoY, but margins fell. ACLS trades at a premium valuation, with a forward P/E of 21.2X. A merger with Veeco Instruments is pending regulatory approval.

Axcelis Technologies (ACLS) is investing $35M in a new Korea facility. Its stock has fallen 25.1% in the past month, but is up 22.0% YTD and 119.5% over 5 years. Analysts debate its valuation, with a fair value estimate of $161 vs. a recent close of $105.04, citing growth potential in silicon carbide (SiC) demand.

Axcelis Technologies (Nasdaq: ACLS) plans to invest $35 million in a new ion implantation equipment manufacturing facility in Pyeongtaek, South Korea. The 200,000 sq. ft. plant will include cleanrooms and a training center, aiming to support global semiconductor demand. Production is set to begin in late 2028, according to the company.

Axcelis Technologies (ACLS) fell 3.03% to $115.56, underperforming major indices. Over the past month, it declined 11.96%, lagging its sector and the S&P 500. Analysts expect Q2 earnings of $1.11 per share (down 8.26% YoY) and revenue of $230.05M (up 7.7% YoY). The stock has a Zacks Rank of #3 (Hold) and trades at a Forward P/E of 28.92, below its industry average.

NVIDIA (NVDA) agreed to acquire Hugging Face for $12.93B. Ambarella (AMBA), Asana (ASAN), Samsara (IOT), and others reported earnings beats. Dell (DELL) and Salesforce (CRM) saw strong AI-driven demand. NIO (NIO) missed revenue estimates. TSMC (TSM) raised chip equipment spending. Meta (META) opposed AI regulation. Broadcom (AVGO) and Microsoft (MSFT) expanded AI chip and reporting initiatives.